These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 12572838

  • 1. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.
    Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M.
    Acta Paediatr Suppl; 2002; 91(439):21-7. PubMed ID: 12572838
    [Abstract] [Full Text] [Related]

  • 2. The value of electrocardiography and echocardiography in distinguishing Fabry disease from sarcomeric hypertrophic cardiomyopathy.
    Junqua N, Legallois D, Segard S, Lairez O, Réant P, Goizet C, Maillard H, Charron P, Milliez P, Labombarda F.
    Arch Cardiovasc Dis; 2020; 113(8-9):542-550. PubMed ID: 32771348
    [Abstract] [Full Text] [Related]

  • 3. Many Faces of Fabry's Cardiomyopathy.
    Jain R, Kalvin L, Johnson B, Muthukumar L, Khandheria BK, Tajik AJ.
    JACC Cardiovasc Imaging; 2018 Apr; 11(4):644-647. PubMed ID: 29361493
    [No Abstract] [Full Text] [Related]

  • 4. Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
    Matsuda J, Kitamura M, Takayama M, Imori Y, Shibuya J, Kubota Y, Sangen H, Nakamura S, Takano H, Asai K, Shimizu W.
    Heart Vessels; 2018 Mar; 33(3):246-254. PubMed ID: 28965135
    [Abstract] [Full Text] [Related]

  • 5. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV, Bundgaard H, Rasmussen ÅK, Sørensen SS, Petersen JH, Køber L, Feldt-Rasmussen U, Petri H.
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [Abstract] [Full Text] [Related]

  • 6. The relationship between electrocardiographic left ventricular hypertrophy criteria and echocardiographic mass in patients undergoing transcatheter aortic valve replacement.
    Sjöberg S, Sundh F, Schlegel T, Maynard C, Rück A, Wagner G, Ugander M.
    J Electrocardiol; 2015 Aug; 48(4):630-6. PubMed ID: 25865909
    [Abstract] [Full Text] [Related]

  • 7. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C, Linhart A, Devereux RB, Schiffmann R.
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Cardiac manifestations in Fabry disease].
    Lappegård KT, Aass H.
    Tidsskr Nor Laegeforen; 2000 Aug 30; 120(20):2395-6. PubMed ID: 11475223
    [Abstract] [Full Text] [Related]

  • 10. Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis.
    Paelinck BP, Bondue A, Robyns T, Eyskens F.
    Acta Cardiol; 2024 Aug 30; 79(6):642-649. PubMed ID: 38869089
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease.
    Namdar M, Steffel J, Jetzer S, Schmied C, Hürlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de Asmundis C, Chierchia GB, Sarkozy A, Lüscher TF, Jenni R, Duru F, Brugada P.
    Am J Cardiol; 2012 Feb 15; 109(4):587-93. PubMed ID: 22105784
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy.
    Hoigné P, Attenhofer Jost CH, Duru F, Oechslin EN, Seifert B, Widmer U, Frischknecht B, Jenni R.
    Int J Cardiol; 2006 Aug 28; 111(3):413-22. PubMed ID: 16307805
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS, Lewis NT, Nicholls KM.
    Heart; 2015 Feb 28; 101(4):287-93. PubMed ID: 25381325
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of Electrocardiographic Voltage to Determine Myocardial Fibrosis in Hypertrophic Cardiomyopathy.
    Konno T, Nagata Y, Teramoto R, Fujino N, Nomura A, Tada H, Sakata K, Furusho H, Takamura M, Nakamura H, Kawashiri MA, Yamagishi M, Hayashi K.
    Am J Cardiol; 2016 Feb 01; 117(3):443-9. PubMed ID: 26705881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A.
    Circulation; 2004 Aug 31; 110(9):1047-53. PubMed ID: 15313943
    [Abstract] [Full Text] [Related]

  • 20. Correlation between echocardiographic left ventricular mass index and electrocardiographic variables used in left ventricular hypertrophy criteria in Chinese hypertensive patients.
    Xie L, Wang Z.
    Hellenic J Cardiol; 2010 Aug 31; 51(5):391-401. PubMed ID: 20876051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.